...
首页> 外文期刊>European radiology >Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2*value as a predictive biomarker
【24h】

Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2*value as a predictive biomarker

机译:对肺转移性肾细胞癌抗血管生成靶向治疗的反应评估:R2 *值作为预测生物标志物

获取原文
获取原文并翻译 | 示例

摘要

To evaluate the utility of MR R2*-mapping and the optimal time-point for assessing the response of pulmonary metastatic renal cell carcinoma (mRCC) to anti-angiogenic targeted therapy (aATT).
机译:评估R2 * -MAPPAPT先生和评估肺转移性肾细胞癌(MRCC)对抗血管生成靶向治疗(AATT)响应的最佳时间点的效用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号